Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial After ≥2 years of follow-up

Thomas Powles*, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon-Ching, Jing Wang, Bo Huang, Robert J. Laliberte, Alessandra Di Pietro, Petros Grivas

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

158   Link opens in a new tab Citations (Scopus)
64 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial After ≥2 years of follow-up'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology